Otonomy Inc. (NASDAQ:OTIC) insider Carl Lebel sold 10,625 shares of the firm’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $18.07, for a total value of $191,993.75. Following the completion of the sale, the insider now directly owns 13,001 shares in the company, valued at approximately $234,928.07. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Otonomy Inc. (NASDAQ:OTIC) opened at 18.50 on Thursday. Otonomy Inc. has a one year low of $10.50 and a one year high of $30.75. The company’s 50 day moving average price is $16.76 and its 200-day moving average price is $15.93. The stock’s market capitalization is $558.59 million.

Hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its stake in Otonomy by 29.5% in the second quarter. California State Teachers Retirement System now owns 50,393 shares of the biopharmaceutical company’s stock worth $800,000 after buying an additional 11,467 shares during the period. Rothschild Asset Management Inc. bought a new stake in Otonomy during the second quarter valued at about $249,000. Jennison Associates LLC raised its stake in Otonomy by 8.6% in the second quarter. Jennison Associates LLC now owns 3,876,468 shares of the biopharmaceutical company’s stock valued at $61,558,000 after buying an additional 306,723 shares in the last quarter. Alps Advisors Inc. raised its stake in Otonomy by 28.7% in the second quarter. Alps Advisors Inc. now owns 42,304 shares of the biopharmaceutical company’s stock valued at $672,000 after buying an additional 9,425 shares in the last quarter. Finally, Emerald Acquisition Ltd. bought a new stake in Otonomy during the second quarter valued at about $153,000. Institutional investors own 84.57% of the company’s stock.

Several analysts have weighed in on OTIC shares. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $32.00 price target on shares of Otonomy in a report on Wednesday, November 2nd. Zacks Investment Research raised Otonomy from a “sell” rating to a “hold” rating in a report on Thursday, September 15th.

COPYRIGHT VIOLATION WARNING: “Carl Lebel Sells 10,625 Shares of Otonomy Inc. (OTIC) Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/24/carl-lebel-sells-10625-shares-of-otonomy-inc-otic-stock.html.

Otonomy Company Profile

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration.

5 Day Chart for NASDAQ:OTIC

Receive News & Stock Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related stocks with our FREE daily email newsletter.